Anthem Biosciences' Q2 FY 2025-26 Quarterly Results

Result Summary

• Anthem Biosciences Ltd reported a 6.3% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Sep (Q2 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a - of -.
• Its expenses for the quarter were down by 2.2% QoQ and - - YoY.
• The net profit increased 27.7% QoQ and - - YoY.
• The earnings per share (EPS) of Anthem Biosciences Ltd stood at 3.06 during Q2 FY 2025-26.

Financial Statments for Q2 FY 2025-26

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Anthem Biosciences Ltd operates in the biotechnology sector, focusing on the development and manufacture of advanced pharmaceutical products and services. The company is known for its contributions to the creation of Active Pharmaceutical Ingredients (APIs), intermediates, and specialty chemicals. Anthem Biosciences holds a significant position in the pharmaceutical industry, providing critical resources for drug discovery and development. As of the latest available data, there have been no major developments or disruptions reported that could have affected the company's operations in the most recent quarter.

Revenue

In the second quarter of the fiscal year 2026 (Q2FY26), Anthem Biosciences Ltd recorded a total income of ₹598.26 crores, showing a quarter-over-quarter (QoQ) increase of 6.3% compared to ₹563.02 crores in the first quarter of the fiscal year 2026 (Q1FY26). Year-over-year (YoY) comparisons are not available as the data for the second quarter of the fiscal year 2025 (Q2FY25) is unspecified. The increase in total income indicates a positive momentum in revenue generation for the company during this period. The financial data does not specify details about revenue sources, thus focusing solely on the overall income figures.

Profitability

Anthem Biosciences Ltd's profitability metrics for Q2FY26 demonstrate an upward movement compared to the previous quarter. The Profit Before Tax (PBT) for Q2FY26 was ₹229.60 crores, marking a significant QoQ increase of 23.3% from ₹186.25 crores in Q1FY26. The company's Profit After Tax (PAT) also rose to ₹173.43 crores in Q2FY26, reflecting a 27.7% QoQ growth from ₹135.79 crores in Q1FY26. This increase in profitability is mirrored in the Earnings Per Share (EPS), which climbed from ₹2.42 in Q1FY26 to ₹3.06 in Q2FY26, signifying a QoQ increase of 26.4%. The data for YoY comparison is unavailable, so annual trends cannot be discerned from the provided figures.

Operating Metrics

Operating metrics for Anthem Biosciences Ltd indicate a reduction in total expenses, suggesting improved operational efficiency. Total expenses for Q2FY26 amounted to ₹368.65 crores, which is a decrease of 2.2% from ₹376.78 crores recorded in Q1FY26. This reduction in expenses could correlate with the enhanced profitability observed in this quarter. The tax expense in Q2FY26 was ₹56.17 crores, up 11.3% from ₹50.46 crores in the previous quarter, aligning with the increased profitability and consequent higher tax liabilities. Due to the absence of YoY data for these metrics, longer-term operational trends remain unspecified.